Compare CCAP & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCAP | CMPS |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.6M | 598.7M |
| IPO Year | N/A | 2020 |
| Metric | CCAP | CMPS |
|---|---|---|
| Price | $14.93 | $6.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $16.50 | $16.43 |
| AVG Volume (30 Days) | 194.2K | ★ 1.5M |
| Earning Date | 11-12-2025 | 11-04-2025 |
| Dividend Yield | ★ 11.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $172,891,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.03 | $2.25 |
| 52 Week High | $20.19 | $7.09 |
| Indicator | CCAP | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 68.86 |
| Support Level | $14.15 | $4.90 |
| Resistance Level | $15.13 | $6.93 |
| Average True Range (ATR) | 0.29 | 0.36 |
| MACD | 0.11 | 0.20 |
| Stochastic Oscillator | 88.44 | 94.71 |
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.